Amolyt Pharma, a Lyon, France-based firm specialised in growing therapeutic peptides for uncommon endocrine and associated ailments, raised $138M in Series C funding.
The spherical was co-led by Sofinnova Partners and Intermediate Capital Group, with participation from Tekla Capital Investment LLC, CTI Life Sciences, Andera Partners, Novo Holdings, Kurma Partners, EQT Life Sciences, Innobio 2, Sectoral Asset Management, Pontifax, Orbimed, Mass General Brigham Ventures, ATEM, Credit Agricole Creation and Relyens Innovation Santé/Turenne Capital.
The firm intends to make use of the funds to advance its pipeline of therapeutics for uncommon endocrine and associated problems, together with AZP-3601, now often called eneboparatide, for the therapy of hypoparathyroidism, and AZP-3813 for the therapy of acromegaly.
Led by CEO Thierry Abribat, Amolyt Pharma is a scientific stage biotechnology firm constructing on its crew’s established experience to ship life-changing therapies to sufferers affected by uncommon endocrine and associated ailments. Its improvement portfolio consists of eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a possible therapy for hypoparathyroidism, and AZP-3813, a peptide development hormone receptor antagonist for the potential therapy of acromegaly.